BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23305429)

  • 1. Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series.
    Crispo A; Barba M; D'Aiuto G; De Laurentiis M; Grimaldi M; Rinaldo M; Caolo G; D'Aiuto M; Capasso I; Esposito E; Amore A; Di Bonito M; Botti G; Montella M
    BMC Cancer; 2013 Jan; 13():15. PubMed ID: 23305429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
    Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
    Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mode of detection: an independent prognostic factor for women with breast cancer.
    Hofvind S; Holen Å; Román M; Sebuødegård S; Puig-Vives M; Akslen L
    J Med Screen; 2016 Jun; 23(2):89-97. PubMed ID: 26582492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between screen-detected and symptomatic breast cancers according to molecular subtypes.
    Kim J; Lee S; Bae S; Choi MY; Lee J; Jung SP; Kim S; Choe JH; Kim JH; Kim JS; Lee JE; Nam SJ; Yang JH
    Breast Cancer Res Treat; 2012 Jan; 131(2):527-40. PubMed ID: 22042364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up.
    Falck AK; Röme A; Fernö M; Olsson H; Chebil G; Bendahl PO; Rydén L
    Br J Surg; 2016 Apr; 103(5):513-23. PubMed ID: 26856820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials.
    Shen Y; Yang Y; Inoue LY; Munsell MF; Miller AB; Berry DA
    J Natl Cancer Inst; 2005 Aug; 97(16):1195-203. PubMed ID: 16106024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of clinicopathological characteristics and long-term survival outcomes between symptomatic and screen-detected breast cancer in Japanese women.
    Inari H; Shimizu S; Suganuma N; Yoshida T; Nakayama H; Yamanaka T; Yamanaka A; Rino Y; Masuda M
    Breast Cancer; 2017 Jan; 24(1):98-103. PubMed ID: 26868519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk for distant recurrence of breast cancer detected by mammography screening or other methods.
    Joensuu H; Lehtimäki T; Holli K; Elomaa L; Turpeenniemi-Hujanen T; Kataja V; Anttila A; Lundin M; Isola J; Lundin J
    JAMA; 2004 Sep; 292(9):1064-73. PubMed ID: 15339900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival.
    Dawson SJ; Duffy SW; Blows FM; Driver KE; Provenzano E; LeQuesne J; Greenberg DC; Pharoah P; Caldas C; Wishart GC
    Br J Cancer; 2009 Oct; 101(8):1338-44. PubMed ID: 19773756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients.
    Koh VC; Lim JC; Thike AA; Cheok PY; Thu MM; Tan VK; Tan BK; Ong KW; Ho GH; Tan WJ; Tan Y; Salahuddin AS; Busmanis I; Chong AP; Iqbal J; Thilagaratnam S; Wong JS; Tan PH
    Breast Cancer Res Treat; 2015 Jul; 152(2):293-304. PubMed ID: 26077641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of mammography screening attendance and detection mode in predicting breast cancer survival-is there added prognostic value?
    Biesheuvel C; Czene K; Orgeás CC; Hall P
    Cancer Epidemiol; 2011 Dec; 35(6):545-50. PubMed ID: 21470933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of mammographic breast cancer screening in Singapore: a comparison between screen-detected and symptomatic women.
    Wang WV; Tan SM; Chow WL
    Asian Pac J Cancer Prev; 2011; 12(10):2735-40. PubMed ID: 22320984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
    Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
    Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone?
    Wishart GC; Greenberg DC; Britton PD; Chou P; Brown CH; Purushotham AD; Duffy SW
    Br J Cancer; 2008 Jun; 98(11):1741-4. PubMed ID: 18506175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers.
    Irvin VL; Zhang Z; Simon MS; Chlebowski RT; Luoh SW; Shadyab AH; Krok-Schoen JL; Tabung FK; Qi L; Stefanick ML; Schedin P; Jindal S
    JAMA Netw Open; 2020 Jun; 3(6):e207227. PubMed ID: 32602908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening status, tumour subtype, and breast cancer survival: a national population-based analysis.
    O'Brien KM; Mooney T; Fitzpatrick P; Sharp L
    Breast Cancer Res Treat; 2018 Nov; 172(1):133-142. PubMed ID: 30006795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent prognostic value of screen detection in invasive breast cancer.
    Mook S; Van 't Veer LJ; Rutgers EJ; Ravdin PM; van de Velde AO; van Leeuwen FE; Visser O; Schmidt MK
    J Natl Cancer Inst; 2011 Apr; 103(7):585-97. PubMed ID: 21350218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival and Disease-Free Survival by Breast Density and Phenotype in Interval Breast Cancers.
    Sala M; Domingo L; Louro J; Torá-Rocamora I; Baré M; Ferrer J; Carmona-Garcia MC; Barata T; Román M; Macià F; Castells X;
    Cancer Epidemiol Biomarkers Prev; 2018 Aug; 27(8):908-916. PubMed ID: 29853482
    [No Abstract]   [Full Text] [Related]  

  • 19. Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers.
    Defossez G; Quillet A; Ingrand P
    BMC Cancer; 2018 Apr; 18(1):393. PubMed ID: 29625602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour characteristics of bilateral screen-detected cancers and bilateral interval cancers in women participating at biennial screening mammography.
    van Bommel R; Lameijer JRC; Voogd AC; Nederend J; Louwman MWJ; Setz-Pels W; Strobbe LJ; Tjan-Heijnen VCG; Duijm LE
    Eur J Radiol; 2018 Nov; 108():215-221. PubMed ID: 30396659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.